Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies

K. Fujita (Kyoto, Japan), N. Uchida (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)

Source: International Congress 2019 – Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 365
Disease area: Thoracic oncology

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Fujita (Kyoto, Japan), N. Uchida (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan). Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies. 365

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma
Source: Eur Respir J 2001; 18: 45-52
Year: 2001



Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019

Efficacy of an anti-IL13 monoclonal antibody, lebrikizumab, in adults with inadequately controlled asthma is enhanced in those with high periostin levels
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011

Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma
Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence
Year: 2021



Rapid reversal of radiation-induced murine pneumonitis by treatment with the anti-CTGF monoclonal antibody FG-3019
Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases
Year: 2011

Population pharmacokinetics of tralokinumab, an investigational anti-IL-13 monoclonal antibody, in asthmatic and healthy adults
Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases
Year: 2012

Reversing the suppression of T-cells: the role of monoclonal antibodies
Source: International Congress 2015 – Stop immune tolerance in lung cancer!
Year: 2015



Efficacy of inhaled anti-IL-13 mAb in a mouse model of asthma
Source: Annual Congress 2011 - Experimental modulation of airway inflammation
Year: 2011

Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma
Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease
Year: 2010


Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 367s
Year: 2005

Long-term treatment with monoclonal antibodies anti-IgE in severe asthma: Follow-up of ten patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


PD-L1 evaluation with DAKO and BIOCARE antibody for immunotherapy; Same coin different faces
Source: International Congress 2019 – Diagnosis of lung cancer
Year: 2019

Study of regulative effect of anti-IL-4 monoclone antibody on Th1/Th2 in the patients of allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 431s
Year: 2001

A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics
Source: Annual Congress 2010 - New treatments for asthma and COPD
Year: 2010

A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study
Source: Eur Respir J 2007; 30: Suppl. 51, 622s
Year: 2007

B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all?
Source: Virtual Congress 2020 – Rheumatology: understanding connective tissue disease in patients with interstitial lung disease
Year: 2020


Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 37s
Year: 2001

Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005

Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

Anti-endothelial cell antibodies in patients with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 56s
Year: 2007